SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) September 5, 2000
-----------------
Generex Biotechnology Corporation
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-25169 82-049021
- ---------------------------- ------------- ------------------
(State or other jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
33 Harbor Square, Suite 202, Toronto, Ontario Canada M5J 2G2
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code 416/364-2551
------------
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 7. Exhibits
*10.1 Development and License Agreement dated September 5, 2000
between Generex Biotechnology Corporation and Eli Lilly and
Company. This exhibit replaces in its entirety the copy of
this agreement that was filed as an exhibit to a Form 8-K/A
filed by the registrant on September 7, 2000.
* Portions of this exhibit have been omitted pursuant to a request for
confidential treatment.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENEREX BIOTECHNOLOGY CORPORATION
Dated: January 23, 2001 By: /s/ E. Mark Perri
---------------- -------------------------------------
E. Mark Perri, Chairman and CFO